Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukemia and non-Hodgkin’s lymphoma: Dose-limiting myelosuppression without evidence of DNA hypomethylation

PURPOSE: Targeting aberrant DNA hypermethylation in chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL) with decitabine may reverse epigenetic silencing in B-cell malignancies. METHODS: Twenty patients were enrolled in two phase I trials to determine the minimum effective pharmacolog...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Blum, Kristie A., Liu, Zhongfa, Lucas, David M., Chen, Ping, Xie, Zhiliang, Baiocchi, Robert, Benson, Donald M., Devine, Steven M., Jones, Jeffrey, Andritsos, Leslie, Flynn, Joseph, Plass, Christoph, Marcucci, Guido, Chan, Kenneth K., Grever, Michael R., Byrd, John C.
Formato: Artigo
Idioma:Inglês
Publicado: 2010
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2917115/
https://ncbi.nlm.nih.gov/pubmed/20456354
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2010.08213.x
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares